Stuttgart
06.02.26 | 21:55
4,200 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | LifeVantage outlines $185M-$200M revenue target and new $60M buyback amid GLP-1 headwinds and LoveBiome integration | 1 | Seeking Alpha | ||
| Mi | LifeVantage Q2 2026: Gewinnziel erreicht, Umsatzprognose verfehlt | 2 | Investing.com Deutsch | ||
| Mi | LifeVantage announces $0.045 quarterly dividend payable in March | 1 | Investing.com | ||
| LIFEVANTAGE Aktie jetzt für 0€ handeln | |||||
| Mi | LifeVantage CEO Steve Fife to retire in April after nine-year tenure | 3 | Investing.com | ||
| Mi | LifeVantage CEO Steve Fife to retire in April | 1 | Seeking Alpha | ||
| Mi | LifeVantage Non-GAAP EPS of $0.15 in-line, revenue of $48.9M misses by $5.5M | 2 | Seeking Alpha | ||
| Mi | LifeVantage Corporation: LifeVantage Declares Quarterly Dividend | 1 | GlobeNewswire (USA) | ||
| Mi | LifeVantage Corporation: LifeVantage Announces Planned Retirement of Steve Fife and CEO Succession Plan | 321 | GlobeNewswire (Europe) | SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level... ► Artikel lesen | |
| Mi | LifeVantage Corporation: LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026 | 1.654 | GlobeNewswire (Europe) | SALT LAKE CITY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular... ► Artikel lesen | |
| Mi | Lifevantage Corp - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Lifevantage Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 21.01. | LifeVantage Corporation: LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026 | 1 | GlobeNewswire (USA) | ||
| 12.01. | LifeVantage Corporation: LifeVantage Kicked Off 2026 With Global Kickoff, a Virtual Event Showcasing Innovation and Integration | 1 | GlobeNewswire (USA) | ||
| 07.01. | LifeVantage appoints Mike Edwards as chief technology officer | 1 | Investing.com | ||
| 07.01. | LifeVantage Corporation: LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation | 181 | GlobeNewswire (Europe) | SALT LAKE CITY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular... ► Artikel lesen | |
| 10.12.25 | LifeVantage Corporation: LifeVantage to Participate in Water Tower Fireside Chat on Thursday, December 11, 2025 | 1 | GlobeNewswire (USA) | ||
| 09.12.25 | Lifevantage Corp - 8-K, Current Report | - | SEC Filings | ||
| 01.12.25 | Dividendenbekanntmachungen (01.12.2025) | 11.960 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,38 USD 0,3276 EUR ADVANCED DRAINAGE SYSTEMS INC US00790R1041 0,18 USD 0,1551 EUR AGNICO EAGLE MINES... ► Artikel lesen | |
| 12.11.25 | Lifevantage Corp - 8-K, Current Report | - | SEC Filings | ||
| 05.11.25 | LifeVantage outlines $225M-$240M fiscal 2026 revenue target as LoveBiome integration advances | 2 | Seeking Alpha |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 128,98 | -0,05 % | Gilead wins favorable U.S. label update for Yescarta | ||
| ABBVIE | 189,20 | +0,11 % | Aktien New York Ausblick: Keine Tech-Erholung - Eli Lilly steigen kräftig | NEW YORK (dpa-AFX) - Mit Blick auf den Technologiesektor dürften sich die Investoren an den US-Börsen am Mittwoch zurückhalten. Der Nasdaq 100 Index, der am Vortag deutlich gefallen war, dürfte sich... ► Artikel lesen | |
| ELI LILLY | 894,80 | -0,01 % | Abnehmpille schlägt ein: Starker Start ins neue Jahr - Novo Nordisk zeigt Eli Lilly die Rücklichter! | © Foto: Kristian Tuxen Ladegaard Berg - NurPhotoNach einem schwachen Vorjahr meldet sich Novo Nordisk 2026 eindrucksvoll zurück. Die neue Wegovy-Tablette sorgt in den USA für einen starken Marktstart.... ► Artikel lesen | |
| MERCK & CO | 103,20 | 0,00 % | Ihre wichtigsten Termine: Frische Quartalszahlen von: Pepsico, PayPal, Pfizer, AMD, Merck & Co und KSB | © Foto: Jeff Chiu/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
| TEVA | 29,300 | -0,34 % | Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine | ||
| VERTEX PHARMACEUTICALS | 402,50 | -0,45 % | WuXi Biologics Jumps On Pact With Vertex Pharma For T-Cell Engager In Autoimmune Disease | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - WuXi Biologics (2269. HK,WXIBF), a Contract Research, Development, and Manufacturing Organisation, announced on Tuesday that it has signed a license and... ► Artikel lesen | |
| INCYTE | 91,10 | -0,65 % | Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? | ||
| EYEPOINT | 11,035 | 0,00 % | RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline | ||
| ORGANIGRAM GLOBAL | 1,250 | -4,58 % | Organigram Global Inc: Organigram to release fiscal Q1 results Feb. 10 | ||
| IONIS PHARMACEUTICALS | 71,92 | -1,72 % | Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts | ||
| QUANTUM BIOPHARMA | 3,480 | -1,69 % | Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) | TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 30,000 | -3,85 % | XFRA ITH0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AMARIN | 12,500 | 0,00 % | Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on... ► Artikel lesen | |
| MEDPACE | 458,60 | +0,07 % | A Look at Medpace Holdings' Upcoming Earnings Report | ||
| JAZZ PHARMACEUTICALS | 139,35 | -0,46 % | Boehringer Ingelheim Limited: Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer | Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients
Ingelheim, Germany- 12 January, 2026 - Boehringer Ingelheim today announced a strategic... ► Artikel lesen |
LIFEVANTAGE CORPORATION gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIFEVANTAGE CORPORATION finden Sie auf Wallstreet Online.